Real-World experience with efgartigimod in patients with myasthenia gravis.
Efgartigimod
Generalized myasthenia gravis
MG-ADL
Prednisone
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
25 Mar 2024
25 Mar 2024
Historique:
received:
29
01
2024
accepted:
29
02
2024
revised:
28
02
2024
medline:
26
3
2024
pubmed:
26
3
2024
entrez:
26
3
2024
Statut:
aheadofprint
Résumé
Recommendations for the treatment of myasthenia gravis (MG) have been difficult to develop because of limited evidence from large randomized controlled trials. New drugs and treatment approaches have recently been shown to be effective in phase 3 studies in seropositive generalized (g) MG. One such drug is efgartigimod, a human-Fc-fragment of IgG1, with a high affinity for the endosomal FcRn. We conducted a multicenter study to evaluate the real-world clinical and safety effects of efgartigimod in 22 gMG patients. We evaluated the strategies for the timing of re-treatment with it. The participants received a total of 59 efgartigimod -treatment cycles. The median number of cycles was 2 (range 1-6). Twenty patients (86.3%) improved by at least 2 MG-ADL points after the first treatment cycle. The median MG-ADL score at baseline was 6.5 (range: 3-17) and 2.5 (range: 0-9) post-treatment (p < 0.001). A consistent improvement of at least 2 points in the MG-ADL score after each cycle occurs in 18 patients. The effect duration of the treatment was usually between 4 and 12 weeks. Two major clinical patterns of treatment response were found. Treatment with efgartigimod was also associated with significant reductions of prednisone doses Overall, the treatment was safe and associated with only minor adverse events. The single fatality was apparently due tosevere respiratory failure. We found that efgartigimod is clinically effective, may be used as a steroid sparing agent and is generally safe for gMG patients. We recommend a personalized preventive treatment approach until clinical stabilization, followed by discontinuation and periodic evaluations.
Identifiants
pubmed: 38528163
doi: 10.1007/s00415-024-12293-5
pii: 10.1007/s00415-024-12293-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Vincent A, Newsom-Davis J (1985) Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 48(12):1246–1252
doi: 10.1136/jnnp.48.12.1246
pubmed: 4087000
pmcid: 1028609
Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37(2):141–149
doi: 10.1002/mus.20950
pubmed: 18059039
Drachman DB (1994) Myasthenia gravis. N Engl J Med 330(25):1797–1810
doi: 10.1056/NEJM199406233302507
pubmed: 8190158
Berrih-Aknin S, Le Panse R (2014) Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun 52:90–100
doi: 10.1016/j.jaut.2013.12.011
pubmed: 24389034
Dresser L, Wlodarski R, Rezania K, Soliven B (2021) Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med 10(11):2235
doi: 10.3390/jcm10112235
pubmed: 34064035
pmcid: 8196750
McGrogan A, Sneddon S, de Vries CS (2010) The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology 34(3):171–183
doi: 10.1159/000279334
pubmed: 20130418
Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge HW (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17(7):893–902
doi: 10.1111/j.1468-1331.2010.03019.x
pubmed: 20402760
Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87(4):419–425
doi: 10.1212/WNL.0000000000002790
pubmed: 27358333
pmcid: 4977114
Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J, Melms A, Murai H, Nicolle M, Palace J, Richman D, Verschuuren J (2021) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96(3):114–122
doi: 10.1212/WNL.0000000000011124
pubmed: 33144515
pmcid: 7884987
Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375(26):2570–2581
doi: 10.1056/NEJMra1602678
pubmed: 28029925
Jani-Acsadi A, Lisak RP (2010) Myasthenia gravis. Curr Treat Options Neurol 12(3):231–243
doi: 10.1007/s11940-010-0070-0
pubmed: 20842584
Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023–1036
doi: 10.1016/S1474-4422(15)00145-3
pubmed: 26376969
Pascuzzi RM, Coslett HB, Johns TR (1984) Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 15(3):291–298
doi: 10.1002/ana.410150316
pubmed: 6721451
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O’Brien F, Wang JJ, Mantegazza R (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976–986
doi: 10.1016/S1474-4422(17)30369-1
pubmed: 29066163
Meisel A, Annane D, Vu T, Mantegazza R, Katsuno M, Aguzzi R, Frick G, Gault L, Howard JF (2023) Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. J Neurol 270(8):3862–3875
doi: 10.1007/s00415-023-11699-x
pubmed: 37103755
pmcid: 10134722
Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Sivakumar K, Śmiłowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Lowcock R, Vanderkelen M, Leite MI (2023) Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 22(5):395–406
doi: 10.1016/S1474-4422(23)00080-7
pubmed: 37059508
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526–536
doi: 10.1016/S1474-4422(21)00159-9
pubmed: 34146511
Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ (2023) Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 22(5):383–394
doi: 10.1016/S1474-4422(23)00077-7
pubmed: 37059507
Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS (2019) The neonatal Fc receptor (FcRn): a misnomer? Front Immunol 10:1540
doi: 10.3389/fimmu.2019.01540
pubmed: 31354709
pmcid: 6636548
Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, Vankerckhoven B, Verheesen P, Ongenae N, Lykhopiy V, Enriquez FJ, Cho J, Ober RJ, Ward ES, de Haard H, Leupin N (2018) Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest 128(10):4372–4386
doi: 10.1172/JCI97911
pubmed: 30040076
pmcid: 6159959
Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM (2019) Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology 92(23):e2661–e2673
doi: 10.1212/WNL.0000000000007600
pubmed: 31118245
pmcid: 6556100
Riley TR, Douglas JS, Wang C, Bowser KM (2023) An update of the pharmacological treatment options for generalized myasthenia gravis in adults with anti-acetylcholine receptor antibodies. Am J Health Syst Pharm 80(11):652–662
doi: 10.1093/ajhp/zxad035
pubmed: 36775959
Wolfe GI, Ward ES, de Haard H, Ulrichts P, Mozaffar T, Pasnoor M, Vidarsson G (2021) IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis. J Neurol Sci 430:118074
doi: 10.1016/j.jns.2021.118074
pubmed: 34563918
Heo YA (2022) Efgartigimod: first approval. Drugs 82(3):341–348
doi: 10.1007/s40265-022-01678-3
pubmed: 35179720
pmcid: 8855644
VYVGART 2021 (efgartigimod alfa-fcab) injection, for intravenous use. US Food and Drug Administration (FDA) approved product information. Revised December 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761195s000lbl.pdf (Accessed on June 22, 2023).
Nowak RJ, Coffey CS, Goldstein JM, Dimachkie MM, Benatar M, Kissel JT, Wolfe GI, Burns TM, Freimer ML, Nations S, Granit V, Smith AG, Richman DP, Ciafaloni E, Al-Lozi MT, Sams LA, Quan D, Ubogu E, Pearson B, Sharma A, Yankey JW, Uribe L, Shy M, Amato AA, Conwit R, O’Connor KC, Hafler DA, Cudkowicz ME, Barohn RJ (2022) Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study. Neurology 98(4):e376–e389
doi: 10.1212/WNL.0000000000013121
pubmed: 34857535
pmcid: 8793103
Lascano AM, Lalive PH (2021) Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev 20(1):102712
doi: 10.1016/j.autrev.2020.102712
pubmed: 33197578